Long-Acting Amylin Analogue • Coming Soon
A New Pathway for Weight Management
Cagrilintide is a long-acting amylin analogue that works differently from GLP-1 medications. By mimicking the satiety hormone amylin, it promotes fullness through distinct brain pathways. Phase 3 trials showed 11.8% weight loss as monotherapy. Join our waitlist to be notified when available.
11.8%
Avg Body Weight Loss*
68
Week Phase 3 Trial
1x
Weekly Injection
2026
Expected FDA Decision
Coming Soon
A novel amylin analogue offering a different approach to weight management. This medication works through satiety pathways distinct from GLP-1 therapies.
5mg per vial
Potential For
Patients seeking an alternative approach to appetite control, or those who may not tolerate GLP-1 medications well due to gastrointestinal side effects.
The Science
Cagrilintide is a long-acting analogue of amylin, a hormone naturally released by the pancreas alongside insulin after meals. Amylin promotes satiety by signaling fullness to the brain through pathways distinct from GLP-1—offering a complementary approach to appetite control.
Unlike GLP-1 receptor agonists (like semaglutide), cagrilintide targets amylin and calcitonin receptors in the brainstem. This different mechanism may explain why combining cagrilintide with GLP-1 therapy (CagriSema) produces greater weight loss than either alone.
In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy achieved 11.8% average weight loss over 68 weeks—comparable to semaglutide but with a notably lower incidence of nausea and vomiting, making it a potential option for patients who don’t tolerate GLP-1 medications well.
Join the Waitlist
How It Works
Cagrilintide works through a distinct mechanism from GLP-1 medications, targeting satiety through different brain regions.
Mimics natural amylin released by the pancreas, signaling satiety to the area postrema and other brainstem regions involved in appetite control.
Slows the rate at which food leaves the stomach, prolonging feelings of fullness after meals and reducing overall food intake.
Works through different neural pathways than GLP-1, which is why combining cagrilintide with semaglutide (CagriSema) enhances weight loss beyond either alone.
Clinical Trial Results
Cagrilintide offers comparable weight loss to GLP-1 therapies with a potentially better tolerability profile for some patients.
*Phase 3 REDEFINE trial results. Not yet FDA approved.
Potential Benefits
Works through amylin receptors rather than GLP-1, offering an alternative pathway for patients who may not respond optimally to GLP-1 medications alone.
Phase 3 data showed lower rates of nausea and vomiting compared to GLP-1 therapies—potentially better tolerated for some patients.
11.8% average weight loss as monotherapy in Phase 3 trials—clinically significant and comparable to first-generation GLP-1 medications.
When combined with semaglutide (CagriSema), achieved 20-22% weight loss—demonstrating synergy between amylin and GLP-1 pathways.
Amylin helps regulate post-meal glucose levels, with 88% of prediabetic patients in trials returning to normoglycemia.
Once-weekly subcutaneous injection at the therapeutic dose of 2.4mg—simple to incorporate into any routine.
What to Do Now
Cagrilintide isn’t available yet, but you don’t have to wait to start your weight loss journey. Here’s how we can help today.
Sign up to be notified when cagrilintide receives FDA approval and becomes available at BHRC.
Meet with our physicians to discuss FDA-approved options like semaglutide or tirzepatide that are available now.
Begin your weight loss journey with proven therapies while monitoring cagrilintide’s progress through approval.
When cagrilintide becomes available, discuss with your physician whether it’s right for your goals and tolerance profile.
Clinical Trial Status
Cagrilintide has completed Phase 3 clinical trials (the REDEFINE program) by Novo Nordisk. While results are promising, it has not yet received FDA approval for commercial use.
REDEFINE
Phase 3 clinical program evaluating cagrilintide alone and with semaglutide
3,400+
Participants in the REDEFINE 1 trial across multiple countries
Questions
No, cagrilintide is not yet FDA approved. It has completed Phase 3 clinical trials (the REDEFINE program) with positive results, and Novo Nordisk is expected to seek FDA approval. Commercial availability is anticipated in 2026 at the earliest.
Cagrilintide is an amylin analogue that targets amylin and calcitonin receptors, while semaglutide is a GLP-1 receptor agonist. They work through different brain pathways to promote satiety. This is why combining them (CagriSema) produces greater weight loss than either alone—the mechanisms are complementary rather than redundant.
Amylin is a hormone naturally produced by the pancreas and released alongside insulin after meals. It signals fullness to the brain, slows gastric emptying, and helps regulate post-meal blood sugar. Cagrilintide is a long-acting synthetic version that mimics these effects with once-weekly dosing.
Phase 3 data suggests cagrilintide may have lower rates of nausea and vomiting compared to GLP-1 therapies like semaglutide. However, gastrointestinal side effects (nausea, constipation, diarrhea) still occur, typically mild to moderate in severity. Individual tolerance varies, and our physicians can help determine what’s right for you.
CagriSema is a combination of cagrilintide (2.4mg) and semaglutide (2.4mg) in a single weekly injection. In Phase 3 trials, CagriSema achieved 20-22% average weight loss—significantly more than either component alone. It’s also in Phase 3 trials and not yet FDA approved.
Cagrilintide is not yet available outside of clinical trials. Be cautious of any source claiming to sell cagrilintide—these products are unregulated and potentially dangerous. If you’re interested in weight loss treatment now, we offer FDA-approved options like semaglutide and tirzepatide.
Once available, cagrilintide may be particularly suitable for patients who experience significant GI side effects with GLP-1 medications, those seeking an alternative mechanism for appetite control, or as part of combination therapy for enhanced results. Our physicians can help determine the best approach for your individual needs.
Stay Updated
Be the first to know when cagrilintide becomes available. In the meantime, our team can discuss FDA-approved options like semaglutide and tirzepatide.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*Cagrilintide is an investigational medication that has completed Phase 3 clinical trials but is NOT yet FDA approved for commercial sale. The weight loss figures cited (11.8%) are from the REDEFINE 1 trial. Cagrilintide is only available through clinical trial participation until FDA approval. Any source claiming to sell cagrilintide outside of clinical trials is unregulated and potentially dangerous. BHRC does not currently offer cagrilintide. This page is for informational purposes only. Consult with our medical team about FDA-approved weight loss options available today.
